A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1413

Enrollment

INDUSTRY

Sponsor class

Conditions

Overactive Bladder

Interventions

DRUG: Solabegron modified release tablets, low dose
DRUG: Solabegron modified release tablets, high dose
DRUG: Matching Placebo

Sponsor

Velicept Therapeutics, Inc.